- Home
- TCRT vs GNPX Comparison
TCRT vs GNPX Comparison
Compare TCRT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- GNPX
- Stock Information
- Founded
- TCRT 1998
- GNPX 2009
- Country
- TCRT United States
- GNPX United States
- Employees
- TCRT N/A
- GNPX N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- GNPX Health Care
- Exchange
- TCRT Nasdaq
- GNPX Nasdaq
- Market Cap
- TCRT 4.8M
- GNPX 5.5M
- IPO Year
- TCRT N/A
- GNPX 2018
- Fundamental
- Price
- TCRT $2.40
- GNPX $0.23
- Analyst Decision
- TCRT
- GNPX
- Analyst Count
- TCRT 0
- GNPX 0
- Target Price
- TCRT N/A
- GNPX N/A
- AVG Volume (30 Days)
- TCRT 340.3K
- GNPX 24.1M
- Earning Date
- TCRT 11-13-2025
- GNPX 11-12-2025
- Dividend Yield
- TCRT N/A
- GNPX N/A
- EPS Growth
- TCRT N/A
- GNPX N/A
- EPS
- TCRT N/A
- GNPX N/A
- Revenue
- TCRT $6,000.00
- GNPX N/A
- Revenue This Year
- TCRT $5,680,500.00
- GNPX N/A
- Revenue Next Year
- TCRT N/A
- GNPX N/A
- P/E Ratio
- TCRT N/A
- GNPX N/A
- Revenue Growth
- TCRT N/A
- GNPX N/A
- 52 Week Low
- TCRT $1.31
- GNPX $0.14
- 52 Week High
- TCRT $6.20
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- TCRT 51.69
- GNPX 52.43
- Support Level
- TCRT $2.20
- GNPX $0.20
- Resistance Level
- TCRT $2.40
- GNPX $0.32
- Average True Range (ATR)
- TCRT 0.20
- GNPX 0.05
- MACD
- TCRT 0.07
- GNPX 0.01
- Stochastic Oscillator
- TCRT 91.71
- GNPX 34.69
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.